DNASENSE ApS: Financial statements 2019
CVR: 36036869
Source: annual report 2019, Danish Business Authority
01/10/2018 – 30/09/2019
DNASENSE ApS (CVR 36036869) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK 3,379,904 and a net result of DKK 678,650 compared with DKK 524,124 the year before. That is an increase of 47.2% compared with the year before. Equity in the 2019 report amounted to DKK 1,288,676. The solvency ratio was 62.2%. The company had 4 employees in the financial year.
- Gross Profit
- DKK 3,379,904
- Profit/Loss
- DKK 678,650
- Equity
- DKK 1,288,676
- Total Assets
- DKK 2,072,683
- Employees
- 4
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | 3.4 mio. | 679 t. | 1.3 mio. | 4 |
| 2018 | - | 2.3 mio. | 524 t. | 910 t. | 2 |
| 2017 | - | 1.8 mio. | 673 t. | 886 t. | 1 |
| 2016 | - | 1.1 mio. | 359 t. | 513 t. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningAbout DNASENSE ApS
DNASENSE ApS is a Danish company of the type Anpartsselskab based in Aalborg Øst, founded in 2014. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Mads Toft Søndergaard. The board consists of Anders Christian Neto de Sousa Grøn (chair), Anders Mohr Christensen, Henrik Bjørn Nielsen and Manoj Nirmal Dadlani. The company is owned by Clinical-Microbiomics A/S. The company has 15 employees (2018). In 2025, the company reported a gross profit of DKK 7,915,337 and a net result of DKK 894,729. Equity in the 2025 report amounted to DKK 1,639,012.